loader from loading.io

Episode 447 - Raymond L. Benza, MD

I'm Aware That I'm Rare: the phaware® podcast

Release Date: 12/18/2023

Chelsea Price - phaware® interview 464 show art Chelsea Price - phaware® interview 464

I'm Aware That I'm Rare: the phaware® podcast

Chelsea Price shares her experience living with pulmonary arterial hypertension (PAH). She emphasizes the importance of having a good support system, including her church community and connecting with other friends with PAH. Chelsea is grateful for the good days she has and strives to be an active mom for her children. Learn even more about Chelsea and PAH at .  My name is Chelsea Price. I live in St. Louis, Missouri, and I have pulmonary arterial hypertension (PAH). Shortly after I had my second son, I noticed that my endurance had decreased. I grew up playing soccer, competitive...

info_outline
Episode 464 - Chelsea Price show art Episode 464 - Chelsea Price

I'm Aware That I'm Rare: the phaware® podcast

In this episode, Chelsea Price shares her experience living with pulmonary arterial hypertension (PAH). She emphasizes the importance of having a good support system, including her church community and connecting with other friends with PAH. Chelsea is grateful for the good days she has and strives to be an active mom for her children. Discover even more about Chelsea and PAH at   Learn more about pulmonary hypertension trials at . Follow us on social @phaware Engage for a cure:  #phaware Share your story:    

info_outline
Rajan Saggar, MD - phaware® interview 463 show art Rajan Saggar, MD - phaware® interview 463

I'm Aware That I'm Rare: the phaware® podcast

Dr. Rajan Saggar, a pulmonologist at the University of California in Los Angeles, discusses the complications of pulmonary hypertension in various lung diseases. He explains that pulmonary hypertension can either be its own disease or can complicate other conditions such as heart disease or lung tissue diseases like emphysema or fibrosis. Dr. Saggar mentions a recent FDA-approved medication for pulmonary hypertension complicating lung tissue diseases, and ongoing research to develop more treatments. My name is Rajan Saggar. I'm a pulmonologist. I work out of the University of California in...

info_outline
Episode 463 - Rajan Saggar, MD show art Episode 463 - Rajan Saggar, MD

I'm Aware That I'm Rare: the phaware® podcast

In this episode, Dr. Rajan Saggar, a pulmonologist at the University of California in Los Angeles, discusses the complications of pulmonary hypertension in various lung diseases. He explains that pulmonary hypertension can either be its own disease or can complicate other conditions such as heart disease or lung tissue diseases like emphysema or fibrosis. Dr. Saggar mentions a recent FDA-approved medication for pulmonary hypertension complicating lung tissue diseases, and ongoing research to develop more treatments.  Learn more about pulmonary hypertension trials at . Follow us on...

info_outline
Sandeep Sahay, MD - phaware® interview 462 show art Sandeep Sahay, MD - phaware® interview 462

I'm Aware That I'm Rare: the phaware® podcast

Dr. Sandeep Sahay, a pulmonologist at Houston Methodist Hospital, discusses the concept of disease modification in the treatment of pulmonary hypertension (PH). He explains how traditional PH therapies focus on vasodilation, reducing pressure in the pulmonary artery by dilating blood vessels. However, newer therapies, such as sotatercept, work in different ways to reduce smooth muscle proliferation and thickness of the artery walls. Dr. Sahay suggests that if a drug is labeled as disease-modifying, it may be used in combination with existing PH medications from the beginning of treatment....

info_outline
Episode 462 - Sandeep Sahay, MD show art Episode 462 - Sandeep Sahay, MD

I'm Aware That I'm Rare: the phaware® podcast

In this episode, Dr. Sandeep Sahay, a pulmonologist at Houston Methodist Hospital, discusses the concept of disease modification in the treatment of pulmonary hypertension (PH). He explains how traditional PH therapies focus on vasodilation, reducing pressure in the pulmonary artery by dilating blood vessels. However, newer therapies, such as sotatercept, work in different ways to reduce smooth muscle proliferation and thickness of the artery walls. Dr. Sahay suggests that if a drug is labeled as disease-modifying, it may be used in combination with existing PH medications from the beginning...

info_outline
UNISUS PAH Clinical Trial - phaware® interview 461 show art UNISUS PAH Clinical Trial - phaware® interview 461

I'm Aware That I'm Rare: the phaware® podcast

  SPECIAL EDITION Jonathan Hudson is a Global Trial Leader in Pulmonary Hypertension at Janssen Research & Development and is accompanied by colleague Josephine Garcia-Ferrer, Ph.D and Medical Manager. Jonathan and Josephine discuss Pulmonary Arterial Hypertension (PAH), the importance of clinical trials, what they entail, and share information on Janssen’s . Learn more about UNISUS Study with the . Steve Van Wormer: Hello, and welcome to, I’m Aware That I’m Rare, the phaware® podcast. I’m your host, Steve Van Wormer, from Phaware Global Association. Today, I am...

info_outline
Episode 461 - UNISUS PAH Clinical Trial show art Episode 461 - UNISUS PAH Clinical Trial

I'm Aware That I'm Rare: the phaware® podcast

SPECIAL EDITION: Jonathan Hudson is a Global Trial Leader in Pulmonary Hypertension at Janssen Research & Development and is accompanied by colleague Josephine Garcia-Ferrer, Ph.D and Medical Manager. Jonathan and Josephine discuss Pulmonary Arterial Hypertension (PAH), the importance of clinical trials, what they entail, and share information on Janssen’s . Learn more about UNISUS Study with the . Learn more about pulmonary hypertension trials at . Follow us on social @phaware Engage for a cure:  #phaware Share your story:  

info_outline
Dr. Lewis Romer - phaware® interview 460 show art Dr. Lewis Romer - phaware® interview 460

I'm Aware That I'm Rare: the phaware® podcast

Dr. Lewis Romer discusses his work on the PPHNet's : Mono- vs. Duo-Therapy for Pediatric PAH patients. The Kids Mod PAH study is a research project funded by the NIH that aims to determine the best initial therapy for children with newly diagnosed pulmonary hypertension. The study compares the effectiveness of one medication (sildenafil) versus a combination of two medications (sildenafil and bosentan) in improving the quality of life and functional class of these children.  The study team aims to provide enhanced care and support to the participants and their families throughout the...

info_outline
Episode 460 - Lewis Romer, MD show art Episode 460 - Lewis Romer, MD

I'm Aware That I'm Rare: the phaware® podcast

Dr. Lewis Romer discusses his work on the PPHNet's : Mono- vs. Duo-Therapy for Pediatric PAH patients. The Kids Mod PAH study is a research project funded by the NIH that aims to determine the best initial therapy for children with newly diagnosed pulmonary hypertension. The study compares the effectiveness of one medication (sildenafil) versus a combination of two medications (sildenafil and bosentan) in improving the quality of life and functional class of these children.  The study team aims to provide enhanced care and support to the participants and their families throughout the...

info_outline
 
More Episodes

In this episode, Dr. Raymond Benza, a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses dual therapy in the treatment of pulmonary hypertension (PH) through the concept of risk stratification. 

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware
Share your story: [email protected] #phawareMD @IcahnMountSinai @RaymondBenzaMD